

Rabbit Anti-S100A6 [EP313]: RM0394, RM0394RTU7

Intended Use: For Research Use Only

Description: S100A6, also known as Calcyclin, is a low molecular weight calcium binding protein encoded near the cluster of S100 family genes on chromosome 1. The S100 family of proteins are structurally related and share Ca²⁺ binding domains. Monomers of S100A6 can bind 2 Ca²⁺, but can form homodimers in a Ca²⁺-independent manner. S100A6 is a cytoplasmic and nuclear protein, associating with the plasma membrane and the nuclear envelope in the presence of Ca²⁺. It is abundantly expressed in fibroblasts and epithelial cells. It is also detected in some neurons, glial cells, smooth muscle, myocytes, and lymphocytes. S100A6 has been studied in many human tumors, including pancreatic, melanocytic, gastric, and colorectal cancers. In pancreatic cancer, elevation of S100A6 RNA and protein was observed in malignant cells. Nuclear S100A6 expression is associated with reduced survival time in pancreatic cancer patients. S100A6 expression was also significantly correlated with melanoma metastases and survival times. It was upregulated in 50% of gastric cancers, and highly expressed at the invasive margins of colorectal carcinoma.


Specifications

Clone: EP313
 Source: Rabbit
 Isotype: IgG
 Reactivity: Human
 Localization: Nucleus, cytoplasm
 Formulation: Antibody in PBS pH7.5, containing < 0.2% BSA, 0.09% sodium azide (NaN₃)
 Storage: Store at 2°- 8°C.
 Applications: IHC
 Package:

Description	Catalog No.	Size
S100A6 Concentrated	RM0394	1 ml
S100A6 Prediluted	RM0394RTU7	7 ml

IHC Procedure

Positive Control Tissue: Colon, colon carcinoma
 Concentrated Dilution: 50-200
 Pretreatment: Citrate pH6.0 or EDTA pH8.0, 15 minutes using Pressure Cooker, or 30-60 minutes using water bath at 95°-99°C
 Incubation Time and Temp: 30-60 minutes @ RT
 Detection: Refer to the detection system manual
 * Result should be confirmed by an established diagnostic procedure.



FFPE human endometrial carcinoma stained with anti-S100A6 using DAB

References:

1. Vascular endothelial growth factor receptor 2, but not S100A4 or S100A6, correlates with prolonged survival in advanced urothelial carcinoma. Shah CH, et al. Urol Oncol. Nov;32(8):1215-24, 2014.
2. Aberrant expression of S100A6 and matrix metalloproteinase 9, but not S100A2, S100A4, and S100A7, is associated with epidermal carcinogenesis. Zhu L, et al. J Dermatol Sci. Dec;72(3):311-9, 2013.
3. Decreased expression of S100A6 in oral squamous cell carcinoma. Yang X, et al. Oncol Rep. Aug;24(2):479-88, 2010.

Doc. 100-RM0394
Rev. A